45.67
-1.42 (-3.02%)
| Previous Close | 47.09 |
| Open | 46.89 |
| Volume | 1,464,472 |
| Avg. Volume (3M) | 2,218,020 |
| Market Cap | 8,483,430,912 |
| Price / Earnings (Forward) | 2.50 |
| Price / Sales | 3.05 |
| Price / Book | 3.53 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Profit Margin | -37.29% |
| Operating Margin (TTM) | -4.92% |
| Diluted EPS (TTM) | -5.59 |
| Quarterly Revenue Growth (YOY) | 10.30% |
| Total Debt/Equity (MRQ) | 115.55% |
| Current Ratio (MRQ) | 2.15 |
| Operating Cash Flow (TTM) | 210.54 M |
| Levered Free Cash Flow (TTM) | 61.42 M |
| Return on Assets (TTM) | -1.87% |
| Return on Equity (TTM) | -37.09% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Exact Sciences Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.13 |
|
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 1.07% |
| % Held by Institutions | 100.69% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 73.00 (Scotiabank, 59.84%) | Buy |
| Median | 65.00 (42.33%) | |
| Low | 52.00 (RBC Capital, 13.86%) | Hold |
| Average | 65.00 (42.33%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 50.06 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 13 Mar 2025 | 52.00 (13.86%) | Hold | 43.04 |
| Piper Sandler | 26 Feb 2025 | 70.00 (53.27%) | Buy | 48.50 |
| Scotiabank | 24 Feb 2025 | 73.00 (59.84%) | Buy | 51.28 |
| B of A Securities | 20 Feb 2025 | 65.00 (42.33%) | Buy | 49.51 |
| Barclays | 20 Feb 2025 | 65.00 (42.33%) | Buy | 49.51 |
| 23 Jan 2025 | 70.00 (53.27%) | Buy | 55.13 | |
| Benchmark | 13 Jan 2025 | 65.00 (42.33%) | Buy | 58.51 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |